IRCT201702131457N12 IRCT 2017-06-14 Mazandaran University of Medical Sciences Efficacy of haloperidol on symptom of opium withdrawal. Evaluation of efficacy and safety of Haloperidol on symptoms of acute opioids withdrawal 2017-04-21 anticipated 74 Complete https://irct.ir/trial/730 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 3 Opium use disorder. Intervention 1: patients receiving 15 mg or less than 15 mg of methadone, 5 mg haloperidol will be administered each day; patients receiving 15 to 30 mg of methadone, haloperidol will be administered 10 mg daily; patients receiving 30 to 45 mg of methadone, will be administered 15 mg haloperidol daily; and patients receiving more than 45 mg methadone, will be administered 20 mg haloperidol daily. Haloperidol will be continued for one week after discontinuation of methadone and thereafter it will be reduced half a 5 mg tablet daily until discontinued. Intervention 2: patients receiving 15 mg or less than 15 mg of methadone, 5 mg placebo will be administered each day; patients receiving 15 to 30 mg of methadone, placebo will be administered 10 mg daily; patients receiving 30 to 45 mg of methadone, will be administered 15 mg placebo daily; and patients receiving more than 45 mg methadone, will be administered 20 mg placebo daily. Placebo will be continued for one week after discontinuation of methadone and thereafter it will be reduced half a 5 mg tablet daily until discontinued.